CS
VIR icon

Candriam SCA’s Vir Biotechnology VIR Stock Holding History

Candriam SCA’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.38M Sell
626,690
-509,073
-45% -$4.84M 0.03% 354
2026
Q1 		$10.2M Buy
1,135,763
+104,100
+10% +$829K 0.05% 280
2025
Q4 		$6.22M Buy
+1,031,663
New +$6.14M 0.03% 348
2023
Q4 		– Sell
-11,026
Closed – – 727
2023
Q3 		$0 Sell
11,026
-343,619
-97% -$4.9M ﹤0.01% 692
2023
Q2 		$8.7M Buy
+354,645
New +$8.91M 0.06% 263
2021
Q2 		– Sell
-226,238
Closed -$5.82M – 942
2021
Q1 		$5.82M Hold
226,238
– – 0.05% 347
2020
Q4 		$6.06M Buy
226,238
+20,616
+10% +$670K 0.05% 356
2020
Q3 		$7.06M Buy
+205,622
New +$8.85M 0.07% 292

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Candriam SCA's VIR Position: Q2 2026 in Review

Candriam SCA reduced its Vir Biotechnology (VIR) stake by 45% in Q2 2026, selling an estimated $4.84M and leaving 626,690 shares worth $6.38M. The position accounts for 0.03% of the portfolio, ranked #354.

Candriam SCA first reported a position in VIR in Q3 2020 and has held it in 8 quarters since. The position peaked at $10.2M in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Candriam SCA held 626,690 shares of Vir Biotechnology worth $6.38M as of Q2 2026.
  • Candriam SCA sold 509,073 Vir Biotechnology shares in Q2 2026, an estimated $4.84M.
  • Vir Biotechnology made up 0.03% of Candriam SCA's portfolio in Q2 2026, its #354 holding.
  • Candriam SCA first reported a position in Vir Biotechnology in Q3 2020 and has held it in 8 quarters since.
  • Candriam SCA's Vir Biotechnology position peaked at $10.2M in Q1 2026.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.